Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia
Study Details
Study Description
Brief Summary
To assess the effectiveness of aripiprazole once-monthly in the maintenance treatment of patients with a diagnosis of schizophrenia as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR®), in a naturalistic care setting by comparing it to an existing long-acting antipsychotic, paliperidone palmitate.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Aripiprazole and aripiprazole once-monthly
|
Drug: Aripiprazole and aripiprazole once-monthly
Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection at the end of Week 4. Oral tablets were taken for 2 more weeks after the 1st injection. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
Other Names:
|
| Active Comparator: Paliperidone and paliperidone palmitate
|
Drug: Paliperidone and paliperidone palmitate
Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by 2 paliperidone palmitate IM injections at Weeks 3 and 4, respectively. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Change From Baseline to Week 28 in Quality of Life Scale (QLS) Total Score [Baseline, Week 28]
The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). Definitions were provided for 4 anchor points of the 7 points. Each item had a brief description of the judgement to be made and a set of suggested probes for the clinician. The total score was calculated as the sum of all 21 items giving a range of 0 to 126, where the higher score indicated normal or unimpaired functioning.
Secondary Outcome Measures
- Investigator's Assessment Questionnaire (IAQ) Total Score at Week 28 [Week 28]
The IAQ is a clinician-rated scale designed to assess the relative effectiveness (efficacy, safety and tolerability) of antipsychotic medications in patients with schizophrenia or schizoaffective disorder. The IAQ consists of 12 items: positive symptoms, negative symptoms, other efficacy symptoms, cognition, energy, mood, somnolence, weight gain, signs and symptoms of prolactin elevation, akathisia, EPS (other than akathisia) and other safety or tolerability issues. For each item, the current medication was compared with previous antipsychotic medication on a five-point scale from 1 (Much better) to 5 (Much worse), or that item is Not applicable. The sum of the 12 items ranged from 12 (the current medication was much better than previous antipsychotic medication) to 60 (the current medication was much worse than previous antipsychotic medication).
- Change From Baseline to Week 28 in CGI-S Score [Baseline, Week 28]
Clinical Global Impression - Severity of Illness (CGI-S) score provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).
- Change From Baseline to Week 28 in the 'Common Objects and Activities' QLS Domain Score [Baseline, Week 28]
The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Common Objects and Activities domain score was calculated as the sum of 2 items (numbers 18 and 19) giving a range of 0 to 12, where the higher score indicated less unimpaired functioning.
- Change From Baseline to Week 28 in the 'Intrapsychic Foundations' QLS Domain Score [Baseline, Week 28]
The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Intrapsychic Foundations domain score was calculated as the sum of 7 items (numbers 13 to 17 and 20 and 21) giving a range of 0 to 42, where the higher score indicated less unimpaired functioning.
- Change From Baseline to Week 28 in the 'Interpersonal Relations' QLS Domain Score [Baseline, Week 28]
The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Interpersonal Relations domain score was calculated as the sum of 8 items (numbers 1 to 8) giving a range of 0 to 48, where the higher score indicated less unimpaired functioning.
- Change From Baseline to Week 28 in the 'Instrumental Role' QLS Domain Score [Baseline, Week 28]
The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Instrumental Role domain score was calculated as the sum of 4 items (numbers 9 to 12) giving a range of 0 to 24, where the higher score indicated less unimpaired functioning.
- Change From Baseline to Week 28 in SWN-S Total Score [Baseline, Week 28]
The SWN-S is a patient-rated scale designed to measure subjective effects of neuroleptic drugs to psychopathology, quality of life, and compliance over the past 7 days. The 20 items (10 positive and 10 negative statements) are grouped in 5 subscales (mental functioning, self-control, physical functioning, emotional regulation and social integration). Each subscale contains 4 items. Each item was rated on a six-point Likert scale, from not at all to very much. A score was calculated for each subscale, and the total score ranged from 20 to 120, where the higher score indicated better well-being.
- Change From Baseline to Week 28 in the TooL Total Score [Baseline, Week 28]
Tolerability and Quality of Life (TooL) is a patient-rated scale developed to measure the impact of side-effects on the quality of life in patients treated with antipsychotic medication. The TooL consists of 8 domains: mood (worry-upset), function capabilities, fatigue-weakness, weight gain, stiffness-tremor, physical restlessness, sexual dysfunction, and dizziness-nausea. Each domain was rated on a four-point scale from 1 (no impact) to 4 (maximum impact). Total scores ranged from 8 (no impact) to 32 (maximum impact).
Eligibility Criteria
Criteria
Main Inclusion Criteria:
-
The patient has schizophrenia, diagnosed according to DSM-IV-TR®.
-
The patient has a CGI-S score from mildly ill to markedly ill at the Screening and Baseline Visit(s).
-
The patient is in need of a change in the current antipsychotic treatment and in the judgement of the investigator the patient would benefit from an extended treatment with a once-monthly formulation.
-
The patient agrees to protocol-defined use of effective contraception.
Main Exclusion Criteria:
-
The patient has any current psychiatric disorder or Axis I disorder (DSM-IV® criteria) other than schizophrenia established as the primary diagnosis.
-
The patient is experiencing acute exacerbation of psychotic symptoms at the Screening Visit or between the Screening and Baseline Visits.
-
The patient in the investigator's judgment has shown significant intolerance and/or lack of efficacy to oral aripiprazole, paliperidone or risperidone.
-
The patient is at significant risk of harming himself/herself or others according to the investigator's judgement or according to Columbia-Suicide Severity Rating Scale (C-SSRS).
-
The patient has a history of neuroleptic malignant syndrome.
-
The patient has or has had significant medical condition that would expose him or her to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the study including, but not limited to neurological, hepatic, renal, metabolic, haematological, immunological, gastrointestinal, pulmonary, or cardiovascular disorders.
-
The patient has a disease or takes medication that could, in the investigator's opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the study.
-
The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | US002 | Los Angeles | California | United States | 90660 |
| 2 | US006 | San Diego | California | United States | 92102 |
Sponsors and Collaborators
- H. Lundbeck A/S
- Otsuka Pharmaceutical Co., Ltd.
Investigators
- Study Director: Email contact via H. Lundbeck A/S, LundbeckClinicalTrials@lundbeck.com
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 14724A
- 2012-002785-12
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Aripiprazole | Paliperidone |
|---|---|---|
| Arm/Group Description | Aripiprazole and aripiprazole once-monthly: Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection. Oral tablets will be taken for 2 more weeks after the 1st injection. Additional injections every 4 weeks until Week 24 | Paliperidone and paliperidone palmitate: Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by paliperidone palmitate IM injections every 4 weeks with last dose at Week 24 according to SmPC/USPI |
| Period Title: Overall Study | ||
| STARTED | 148 | 147 |
| COMPLETED | 100 | 83 |
| NOT COMPLETED | 48 | 64 |
Baseline Characteristics
| Arm/Group Title | Aripiprazole | Paliperidone | Total |
|---|---|---|---|
| Arm/Group Description | Aripiprazole and aripiprazole once-monthly: Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection. Oral tablets will be taken for 2 more weeks after the 1st injection. Additional injections every 4 weeks until Week 24 | Paliperidone and paliperidone palmitate: Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by paliperidone palmitate IM injections every 4 weeks with last dose at Week 24 according to SmPC/USPI | Total of all reporting groups |
| Overall Participants | 148 | 147 | 295 |
| Age (years) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [years] |
42.6
(10.83)
|
41.0
(10.87)
|
41.8
(10.86)
|
| Sex: Female, Male (Count of Participants) | |||
| Female |
59
39.9%
|
59
40.1%
|
118
40%
|
| Male |
89
60.1%
|
88
59.9%
|
177
60%
|
| Race (NIH/OMB) (Count of Participants) | |||
| American Indian or Alaska Native |
0
0%
|
0
0%
|
0
0%
|
| Asian |
1
0.7%
|
3
2%
|
4
1.4%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
0
0%
|
0
0%
|
| Black or African American |
44
29.7%
|
38
25.9%
|
82
27.8%
|
| White |
102
68.9%
|
102
69.4%
|
204
69.2%
|
| More than one race |
0
0%
|
0
0%
|
0
0%
|
| Unknown or Not Reported |
1
0.7%
|
4
2.7%
|
5
1.7%
|
Outcome Measures
| Title | Change From Baseline to Week 28 in Quality of Life Scale (QLS) Total Score |
|---|---|
| Description | The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). Definitions were provided for 4 anchor points of the 7 points. Each item had a brief description of the judgement to be made and a set of suggested probes for the clinician. The total score was calculated as the sum of all 21 items giving a range of 0 to 126, where the higher score indicated normal or unimpaired functioning. |
| Time Frame | Baseline, Week 28 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Effectiveness data is based on all patients who received study medicine, who had a valid baseline assessment, and at least 1 valid post-baseline assessment of the QLS (Full analysis set). Effectiveness was measured at Weeks 0, 4, 8, 16, and 28. |
| Arm/Group Title | Aripiprazole | Paliperidone |
|---|---|---|
| Arm/Group Description | Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection at the end of Week 4. Oral tablets were taken for 2 more weeks after the 1st injection. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24. | Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by 2 paliperidone palmitate IM injections at Weeks 3 and 4, respectively. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24. |
| Measure Participants | 136 | 132 |
| Least Squares Mean (Standard Error) [units on a scale] |
7.47
(1.53)
|
2.80
(1.62)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Aripiprazole, Paliperidone |
|---|---|---|
| Comments | Comparison of aripiprazole versus paliperidone was made using estimates from a mixed model for repeated measurements (MMRM) using an unstructured covariance matrix. | |
| Type of Statistical Test | Non-Inferiority or Equivalence | |
| Comments | Non-inferiority of the primary endpoint was considered confirmed if the lower bound of the 2-sided 95% CI at Week 28 was > -5 or equivalently if the p-value for the 1-sided test of H0: D ≤ -5 against H1: D > -5 was ≤2.5%, where D was the mean treatment difference (aripiprazole minus paliperidone). Superiority was then tested as pre-specified with the FAS and demonstrated for aripiprazole over paliperidone, since the lower bound of the 95% CI was >0. | |
| Statistical Test of Hypothesis | p-Value | 0.036 |
| Comments | ||
| Method | Mixed Models Analysis | |
| Comments | The model uses an unstructured variance/covariance matrix. | |
| Method of Estimation | Estimation Parameter | Least Squares Mean Difference |
| Estimated Value | 4.666 | |
| Confidence Interval |
(2-Sided) 95% 0.316 to 9.015 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Investigator's Assessment Questionnaire (IAQ) Total Score at Week 28 |
|---|---|
| Description | The IAQ is a clinician-rated scale designed to assess the relative effectiveness (efficacy, safety and tolerability) of antipsychotic medications in patients with schizophrenia or schizoaffective disorder. The IAQ consists of 12 items: positive symptoms, negative symptoms, other efficacy symptoms, cognition, energy, mood, somnolence, weight gain, signs and symptoms of prolactin elevation, akathisia, EPS (other than akathisia) and other safety or tolerability issues. For each item, the current medication was compared with previous antipsychotic medication on a five-point scale from 1 (Much better) to 5 (Much worse), or that item is Not applicable. The sum of the 12 items ranged from 12 (the current medication was much better than previous antipsychotic medication) to 60 (the current medication was much worse than previous antipsychotic medication). |
| Time Frame | Week 28 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Effectiveness data is based on all patients who received study medicine, who had a valid baseline assessment, and at least 1 valid post-baseline assessment of the QLS (Full analysis set). Effectiveness was measured at Weeks 4, 8, 16, and 28. Since the IAQ was assessed from week 4, the analysis was based on 133 and 131 patients |
| Arm/Group Title | Aripiprazole | Paliperidone |
|---|---|---|
| Arm/Group Description | Aripiprazole and aripiprazole once-monthly: Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection. Oral tablets will be taken for 2 more weeks after the 1st injection. Additional injections every 4 weeks until Week 24 | Paliperidone and paliperidone palmitate: Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by paliperidone palmitate IM injections every 4 weeks with last dose at Week 24 according to SmPC/USPI |
| Measure Participants | 133 | 131 |
| Least Squares Mean (Standard Error) [units on a scale] |
32.32
(0.52)
|
33.81
(0.55)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Aripiprazole, Paliperidone |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.043 |
| Comments | All secondary endpoints were tested without any hierarchical testing strategy and no adjustment for multiplicity | |
| Method | Mixed Models Analysis | |
| Comments | The model uses an unstructured variance/covariance matrix. | |
| Method of Estimation | Estimation Parameter | Least Squares Mean Difference |
| Estimated Value | -1.492 | |
| Confidence Interval |
(2-Sided) 95% -2.935 to -0.049 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Change From Baseline to Week 28 in CGI-S Score |
|---|---|
| Description | Clinical Global Impression - Severity of Illness (CGI-S) score provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients). |
| Time Frame | Baseline, Week 28 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Effectiveness data is based on all patients who received study medicine, who had a valid baseline assessment, and at least 1 valid post-baseline assessment of the QLS (Full analysis set). Effectiveness was measured at Weeks 0, 4, 8, 16, and 28. |
| Arm/Group Title | Aripiprazole | Paliperidone |
|---|---|---|
| Arm/Group Description | Aripiprazole and aripiprazole once-monthly: Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection. Oral tablets will be taken for 2 more weeks after the 1st injection. Additional injections every 4 weeks until Week 24 | Paliperidone and paliperidone palmitate: Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by paliperidone palmitate IM injections every 4 weeks with last dose at Week 24 according to SmPC/USPI |
| Measure Participants | 136 | 132 |
| Least Squares Mean (Standard Error) [units on a scale] |
-0.75
(0.07)
|
-0.46
(0.07)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Aripiprazole, Paliperidone |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.004 |
| Comments | All secondary endpoints were tested without any hierarchical testing strategy and no adjustment for multiplicity | |
| Method | Mixed Models Analysis | |
| Comments | The model uses an unstructured variance/covariance matrix. | |
| Method of Estimation | Estimation Parameter | Least Squares Mean Difference |
| Estimated Value | -0.283 | |
| Confidence Interval |
(2-Sided) 95% -0.477 to -0.090 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Change From Baseline to Week 28 in the 'Common Objects and Activities' QLS Domain Score |
|---|---|
| Description | The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Common Objects and Activities domain score was calculated as the sum of 2 items (numbers 18 and 19) giving a range of 0 to 12, where the higher score indicated less unimpaired functioning. |
| Time Frame | Baseline, Week 28 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Effectiveness data is based on all patients who received study medicine, who had a valid baseline assessment, and at least 1 valid post-baseline assessment of the QLS (Full analysis set). Effectiveness was measured at Weeks 0, 4, 8, 16, and 28. |
| Arm/Group Title | Aripiprazole | Paliperidone |
|---|---|---|
| Arm/Group Description | Aripiprazole and aripiprazole once-monthly: Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection. Oral tablets will be taken for 2 more weeks after the 1st injection. Additional injections every 4 weeks until Week 24 | Paliperidone and paliperidone palmitate: Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by paliperidone palmitate IM injections every 4 weeks with last dose at Week 24 according to SmPC/USPI |
| Measure Participants | 136 | 132 |
| Least Squares Mean (Standard Error) [units on a scale] |
0.52
(0.16)
|
0.18
(0.17)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Aripiprazole, Paliperidone |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.149 |
| Comments | All secondary endpoints were tested without any hierarchical testing strategy and no adjustment for multiplicity | |
| Method | Mixed Models Analysis | |
| Comments | The model uses an unstructured variance/covariance matrix. | |
| Method of Estimation | Estimation Parameter | Least Squares Mean Difference |
| Estimated Value | 0.331 | |
| Confidence Interval |
(2-Sided) 95% -0.120 to 0.782 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Change From Baseline to Week 28 in the 'Intrapsychic Foundations' QLS Domain Score |
|---|---|
| Description | The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Intrapsychic Foundations domain score was calculated as the sum of 7 items (numbers 13 to 17 and 20 and 21) giving a range of 0 to 42, where the higher score indicated less unimpaired functioning. |
| Time Frame | Baseline, Week 28 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Effectiveness data is based on all patients who received study medicine, who had a valid baseline assessment, and at least 1 valid post-baseline assessment of the QLS (Full analysis set). Effectiveness was measured at Weeks 0, 4, 8, 16, and 28. |
| Arm/Group Title | Aripiprazole | Paliperidone |
|---|---|---|
| Arm/Group Description | Aripiprazole and aripiprazole once-monthly: Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection. Oral tablets will be taken for 2 more weeks after the 1st injection. Additional injections every 4 weeks until Week 24 | Paliperidone and paliperidone palmitate: Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by paliperidone palmitate IM injections every 4 weeks with last dose at Week 24 according to SmPC/USPI |
| Measure Participants | 136 | 132 |
| Least Squares Mean (Standard Error) [units on a scale] |
2.25
(0.59)
|
0.50
(0.63)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Aripiprazole, Paliperidone |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.039 |
| Comments | All secondary endpoints were tested without any hierarchical testing strategy and no adjustment for multiplicity | |
| Method | Mixed Models Analysis | |
| Comments | The model uses an unstructured variance/covariance matrix. | |
| Method of Estimation | Estimation Parameter | Least Squares Mean Difference |
| Estimated Value | 1.753 | |
| Confidence Interval |
(2-Sided) 95% 0.093 to 3.412 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Change From Baseline to Week 28 in the 'Interpersonal Relations' QLS Domain Score |
|---|---|
| Description | The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Interpersonal Relations domain score was calculated as the sum of 8 items (numbers 1 to 8) giving a range of 0 to 48, where the higher score indicated less unimpaired functioning. |
| Time Frame | Baseline, Week 28 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Effectiveness data is based on all patients who received study medicine, who had a valid baseline assessment, and at least 1 valid post-baseline assessment of the QLS (Full analysis set). Effectiveness was measured at Weeks 0, 4, 8, 16, and 28. |
| Arm/Group Title | Aripiprazole | Paliperidone |
|---|---|---|
| Arm/Group Description | Aripiprazole and aripiprazole once-monthly: Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection. Oral tablets will be taken for 2 more weeks after the 1st injection. Additional injections every 4 weeks until Week 24 | Paliperidone and paliperidone palmitate: Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by paliperidone palmitate IM injections every 4 weeks with last dose at Week 24 according to SmPC/USPI |
| Measure Participants | 136 | 132 |
| Least Squares Mean (Standard Error) [units on a scale] |
3.24
(0.68)
|
1.47
(0.72)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Aripiprazole, Paliperidone |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.070 |
| Comments | All secondary endpoints were tested without any hierarchical testing strategy and no adjustment for multiplicity | |
| Method | Mixed Models Analysis | |
| Comments | The model uses an unstructured variance/covariance matrix. | |
| Method of Estimation | Estimation Parameter | Least Squares Mean Difference |
| Estimated Value | 1.764 | |
| Confidence Interval |
(2-Sided) 95% -0.143 to 3.672 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Change From Baseline to Week 28 in the 'Instrumental Role' QLS Domain Score |
|---|---|
| Description | The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Instrumental Role domain score was calculated as the sum of 4 items (numbers 9 to 12) giving a range of 0 to 24, where the higher score indicated less unimpaired functioning. |
| Time Frame | Baseline, Week 28 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Effectiveness data is based on all patients who received study medicine, who had a valid baseline assessment, and at least 1 valid post-baseline assessment of the QLS (Full analysis set). Effectiveness was measured at Weeks 0, 4, 8, 16, and 28. |
| Arm/Group Title | Aripiprazole | Paliperidone |
|---|---|---|
| Arm/Group Description | Aripiprazole and aripiprazole once-monthly: Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection. Oral tablets will be taken for 2 more weeks after the 1st injection. Additional injections every 4 weeks until Week 24 | Paliperidone and paliperidone palmitate: Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by paliperidone palmitate IM injections every 4 weeks with last dose at Week 24 according to SmPC/USPI |
| Measure Participants | 136 | 132 |
| Least Squares Mean (Standard Error) [units on a scale] |
1.76
(0.42)
|
0.83
(0.45)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Aripiprazole, Paliperidone |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.130 |
| Comments | All secondary endpoints were tested without any hierarchical testing strategy and no adjustment for multiplicity | |
| Method | Mixed Models Analysis | |
| Comments | The model uses an unstructured variance/covariance matrix. | |
| Method of Estimation | Estimation Parameter | Least Squares Mean Difference |
| Estimated Value | 0.922 | |
| Confidence Interval |
(2-Sided) 95% -0.275 to 2.119 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Change From Baseline to Week 28 in SWN-S Total Score |
|---|---|
| Description | The SWN-S is a patient-rated scale designed to measure subjective effects of neuroleptic drugs to psychopathology, quality of life, and compliance over the past 7 days. The 20 items (10 positive and 10 negative statements) are grouped in 5 subscales (mental functioning, self-control, physical functioning, emotional regulation and social integration). Each subscale contains 4 items. Each item was rated on a six-point Likert scale, from not at all to very much. A score was calculated for each subscale, and the total score ranged from 20 to 120, where the higher score indicated better well-being. |
| Time Frame | Baseline, Week 28 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Effectiveness data is based on all patients who received study medicine, who had a valid baseline assessment, and at least 1 valid post-baseline assessment of the QLS (Full analysis set). Effectiveness was measured at Weeks 0, 4, 8, 16, and 28. |
| Arm/Group Title | Aripiprazole | Paliperidone |
|---|---|---|
| Arm/Group Description | Aripiprazole and aripiprazole once-monthly: Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection. Oral tablets will be taken for 2 more weeks after the 1st injection. Additional injections every 4 weeks until Week 24 | Paliperidone and paliperidone palmitate: Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by paliperidone palmitate IM injections every 4 weeks with last dose at Week 24 according to SmPC/USPI |
| Measure Participants | 136 | 132 |
| Least Squares Mean (Standard Error) [units on a scale] |
4.82
(1.24)
|
3.81
(1.31)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Aripiprazole, Paliperidone |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.561 |
| Comments | All secondary endpoints were tested without any hierarchical testing strategy and no adjustment for multiplicity | |
| Method | Mixed Models Analysis | |
| Comments | The model uses an unstructured variance/covariance matrix. | |
| Method of Estimation | Estimation Parameter | Least Squares Mean Difference |
| Estimated Value | 1.007 | |
| Confidence Interval |
(2-Sided) 95% -2.402 to 4.417 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Change From Baseline to Week 28 in the TooL Total Score |
|---|---|
| Description | Tolerability and Quality of Life (TooL) is a patient-rated scale developed to measure the impact of side-effects on the quality of life in patients treated with antipsychotic medication. The TooL consists of 8 domains: mood (worry-upset), function capabilities, fatigue-weakness, weight gain, stiffness-tremor, physical restlessness, sexual dysfunction, and dizziness-nausea. Each domain was rated on a four-point scale from 1 (no impact) to 4 (maximum impact). Total scores ranged from 8 (no impact) to 32 (maximum impact). |
| Time Frame | Baseline, Week 28 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Effectiveness data is based on all patients who received study medicine, who had a valid baseline assessment, and at least 1 valid post-baseline assessment of the QLS (Full analysis set). Effectiveness was measured at Weeks 0, 4, 8, 16, and 28. |
| Arm/Group Title | Aripiprazole | Paliperidone |
|---|---|---|
| Arm/Group Description | Aripiprazole and aripiprazole once-monthly: Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection. Oral tablets will be taken for 2 more weeks after the 1st injection. Additional injections every 4 weeks until Week 24 | Paliperidone and paliperidone palmitate: Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by paliperidone palmitate IM injections every 4 weeks with last dose at Week 24 according to SmPC/USPI |
| Measure Participants | 136 | 132 |
| Least Squares Mean (Standard Error) [units on a scale] |
-1.75
(0.30)
|
-1.05
(0.32)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Aripiprazole, Paliperidone |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.095 |
| Comments | All secondary endpoints were tested without any hierarchical testing strategy and no adjustment for multiplicity | |
| Method | Mixed Models Analysis | |
| Comments | The model uses an unstructured variance/covariance matrix. | |
| Method of Estimation | Estimation Parameter | Least Squares Mean Difference |
| Estimated Value | -0.695 | |
| Confidence Interval |
(2-Sided) 95% -1.511 to 0.121 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
Adverse Events
| Time Frame | First dose to end of study (32 weeks) | |||
|---|---|---|---|---|
| Adverse Event Reporting Description | ||||
| Arm/Group Title | ARIPIPRAZOLE | PALIPERIDONE | ||
| Arm/Group Description | Safety data is based on all patients who received study medicine. | Safety data is based on all patients who received study medicine. | ||
All Cause Mortality |
||||
| ARIPIPRAZOLE | PALIPERIDONE | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | / (NaN) | / (NaN) | ||
Serious Adverse Events |
||||
| ARIPIPRAZOLE | PALIPERIDONE | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 12/144 (8.3%) | 10/137 (7.3%) | ||
| Hepatobiliary disorders | ||||
| Cirrhosis alcoholic | 0/144 (0%) | 1/137 (0.7%) | ||
| Infections and infestations | ||||
| Gastroenteritis viral | 0/144 (0%) | 1/137 (0.7%) | ||
| Injury, poisoning and procedural complications | ||||
| Head injury | 0/144 (0%) | 1/137 (0.7%) | ||
| Intentional overdose | 1/144 (0.7%) | 0/137 (0%) | ||
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | ||||
| Nasopharyngeal cancer | 0/144 (0%) | 1/137 (0.7%) | ||
| Psychiatric disorders | ||||
| Psychotic disorder | 5/144 (3.5%) | 4/137 (2.9%) | ||
| Schizophrenia | 5/144 (3.5%) | 1/137 (0.7%) | ||
| Suividal ideation | 1/144 (0.7%) | 0/137 (0%) | ||
| Respiratory, thoracic and mediastinal disorders | ||||
| Asthma | 0/144 (0%) | 1/137 (0.7%) | ||
Other (Not Including Serious) Adverse Events |
||||
| ARIPIPRAZOLE | PALIPERIDONE | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 64/144 (44.4%) | 74/137 (54%) | ||
| Gastrointestinal disorders | ||||
| Nausea | 3/144 (2.1%) | 8/137 (5.8%) | ||
| General disorders | ||||
| Fatigue | 4/144 (2.8%) | 7/137 (5.1%) | ||
| Injection site pain | 4/144 (2.8%) | 11/137 (8%) | ||
| Infections and infestations | ||||
| Nasopharyngitis | 6/144 (4.2%) | 8/137 (5.8%) | ||
| Injury, poisoning and procedural complications | ||||
| Accidental overdose | 30/144 (20.8%) | 13/137 (9.5%) | ||
| Investigations | ||||
| Weight increased | 13/144 (9%) | 19/137 (13.9%) | ||
| Nervous system disorders | ||||
| Akathisia | 8/144 (5.6%) | 6/137 (4.4%) | ||
| Dizziness | 5/144 (3.5%) | 12/137 (8.8%) | ||
| Headache | 3/144 (2.1%) | 11/137 (8%) | ||
| Somnolence | 9/144 (6.3%) | 8/137 (5.8%) | ||
| Psychiatric disorders | ||||
| Anxiety | 8/144 (5.6%) | 12/137 (8.8%) | ||
| Insomnia | 17/144 (11.8%) | 17/137 (12.4%) | ||
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Study director |
|---|---|
| Organization | Email contact via H. Ludbeck A/S |
| Phone | |
| LundbeckClinicalTrials@lundbeck.com |
- 14724A
- 2012-002785-12